文献速递骨软组织肉瘤与黑色素瘤

转移性黑色素瘤免疫检查点抑制剂联合靶向治疗的理论依据

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.
PubMed 文献 · JAMA Oncol · 2020-01-01

本综述阐述免疫检查点抑制剂与靶向治疗联合或序贯用于转移性黑色素瘤的理论依据和临床前证据。BRAF/MEK抑制剂可改变肿瘤微环境免疫状态,可能增强BRAF V600突变黑色素瘤对免疫检查点抑制剂的敏感性,联合策略或可延长缓解持续时间、改善肿瘤控制及生存,但最佳时机、疗程和患者选择仍待明确。

要点

  • 靶向治疗可调节肿瘤微环境免疫,支持与免疫检查点抑制剂联合或序贯。
  • 联合策略可能延长缓解持续时间、改善肿瘤控制并延长生存。
  • 最佳时机、疗程和患者选择仍未确定,多项后期试验正在进行。

核心结论

  • 免疫检查点抑制剂联合靶向治疗或序贯策略在转移性黑色素瘤中具有理论依据和临床前证据支持,但最佳时机、疗程及患者选择等临床问题尚待解决。

研究设计与样本

  • 本文为综述,汇总支持免疫检查点抑制剂联合及序贯靶向治疗策略的理论依据、临床前证据和已有临床试验结果。

主要发现

  • BRAF和/或MEK抑制剂的临床缓解与肿瘤微环境免疫改变相关,可能增加BRAF V600突变黑色素瘤对免疫检查点抑制剂的敏感性。
  • 免疫检查点抑制剂联合靶向治疗可能延长缓解持续时间、改善肿瘤控制、延长生存并增加获得持久获益的患者比例。

临床怎么用

  • 联合或序贯策略可能为转移性黑色素瘤提供额外临床获益,但临床决策需考虑最佳时机、疗程和患者选择等未决问题。
  • 多项后期试验正在进行,旨在回答一线联合与序贯的争议,并指导临床实践。

局限性

  • 最佳治疗时机、疗程和患者选择尚未明确。
  • 一线联合与序贯策略的争议持续存在,需等待后期试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In recent years, the management of metastatic melanoma has been transformed by the emergence of immune checkpoint inhibitors and targeted therapies that significantly improve patient survival. The complementary response kinetics of these treatment approaches, supported by mechanistic evidence that targeted therapy affects immune aspects of the tumor microenvironment, suggest that the optimal combination or sequencing of immune checkpoint inhibitors and targeted therapy may provide additional clinical benefit. OBSERVATIONS: Clinical responses to BRAF and/or MEK inhibitors are associated with immune changes within the tumor microenvironment that have the potential to increase the sensitivity of BRAF V600-mutant melanoma to immune checkpoint inhibitors. The combination of immune checkpoint inhibitors with targeted therapy may therefore increase duration of response, improve tumor control, extend survival, and increase the proportion of patients experiencing durable benefit. A targeted therapy-immune checkpoint inhibitor sequencing approach may also be supported by this evidence, but clinical questions regarding optimal timing, duration, and patient selection remain. CONCLUSIONS AND RELEVANCE: This review outlines the rationale and preclinical evidence that support immune checkpoint inhibitor plus targeted therapy combination and sequencing strategies in melanoma and highlights the results available to date from clinical trials exploring these approaches to treatment. Several late-stage trials are under way looking to answer open questions in this field and address the continuing debate surrounding up-front combination vs sequencing. As phase 3 data have begun to emerge, trial designs and available data from key studies are discussed in the context of their resultant implications for clinical practice.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Dummer R, Ascierto PA, Nathan P, et al. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. JAMA Oncol. 2020. PMID: 32970096. doi:10.1001/jamaoncol.2020.4401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。